author-photo

Peter A. Kaufman

University of Vermont Medical Center

13

Papers

82

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Alliance A071701: Genomically guided treatment trial in brain metastases.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status From SystHERs

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (17)
Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (24)